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Background and Objectives: To determine the proportion of type 2 diabetic outpatients with adequate 
control of risk factors for nephropathy in a Nigerian teaching hospital. 
Methods: Between April and July 2005, 160 type 2 diabetic outpatients were assessed for control of 
average fasting blood glucose and blood pressure over 3 visits, and current use of ACE inhibitors. All 
patients were over 30 years of age and had been followed up for at least one year with at least 6 prior clinic 
visits.
Results: We studied 58 male and 102 female subjects with a mean (±SD) age of 54±10 years. The majority 
(54.7%) had diabetes between 1 and 5 years, and 95% were on antidiabetic drugs, most commonly both a 
sulphonylurea and metformin (64.5%). 114 (71.2%) were being treated for hypertension. The mean fasting 
blood glucose (FBS) was 7.6±2.9mmol/L, and 73 (45.6%) had good glycaemic control (mean FBS≤
5.6mmol/L). A total of 51 (31.9%) had good blood pressure control (<140/90mmHg in non-hypertensives 
and <130/80mmHg in hypertensives), and 73 (45.6%) were currently receiving ACE inhibitors. Only five 
(3.1%) had the combination of good glycaemic control, good blood pressure control and received ACE 
inhibitors. Conversely, 23 (14.4%) had a combination of poor glycaemic control, poor blood pressure 
control, and were not receiving ACE inhibitors. Duration of diabetes (p<0.01), elevated creatinine 
(p<0.01), and elevated systolic blood pressure (p<0.01) were independently associated with proteinuria.
Conclusion: Despite the availability of measures to prevent the progression of diabetic nephropathy, 
control of risk factors was poor. Physicians and diabetic patients in Nigeria must work together to improve 
their management of risk factors for nephropathy.
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INTRODUCTION
Diabetic nephropathy, a progressive complication 
of diabetes mellitus, is characterised by persistent 
albuminuria, elevated arterial blood pressure, and a 
relentless decline in glomerular filtration rate [1]. It 
is the leading cause of end-stage renal disease 
(ESRD) in Europe, Japan and the US, accounting 
for 25-30% of cases [2-4]. However, it is the third 
leading cause ESRD in Nigeria, accounting for up 
to 4% of patients with renal failure, behind 
hypertension and glomerulonephritis [5]. 
Multiple factors contribute to the initiation and 
progression of diabetic nephropathy [6]. Preventing 
or delaying progression is therefore an essential 
management goal. In many countries this goal 
remains elusive, despite clinically proven 
prevention strategies and guidelines [7]. The 
primary, potentially modifiable risk factors for 
diabetic nephropathy are sustained hyperglycaemia 
and hypertension. Other putative risk factors 
include glomerular hyperfiltration, smoking, 
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dyslipidaemia, proteinuria and dietary factors [2, 6, 
8-10].
Clinical trials provide clear evidence that long-term 
targeted intensive interventions involving multiple 
risk factors retard the progression of diabetic 
 
nephropathy [3, 5, 9, 10]. Targets have been 
adopted by the World Health Organisation (WHO), 
International Diabetes Federation (IDF), and the 
American Diabetes Association (ADA) regarding 
control of risk factors for diabetic nephropathy [10-
12], which include strict glycaemic control, control 
of hypertension, and early blockade of the renin-
angiotensin-aldosterone system.
We were interested in finding out the use of 
nephropathy prevention strategies among type 2 
diabetics attending the General Out Patients 
Department in a tertiary hospital in Nigeria.
Methods
Consecutive type 2 diabetic outpatients in the 
General Outpatient Department of the Jos 
University Teaching Hospital were recruited 
between April and July 2005. Eligible subjects 
were at least 30 years of age and had been followed 
for at least 6 months with at least 6 prior visits and 
complete medical records. Jos is an urban city 
located in the north central zone of Nigeria. 
Approval for the study was obtained from the 
Ethical Committee of the Jos University Teaching 
Hospital, and each subject provided written 
informed consent.
Each subject was interviewed using a standard 
questionnaire covering personal and disease 
history. Body weight and height were measured 
without shoes with patients in light clothing and the 
body mass index was calculated as the ratio of 
 
weight in kilograms to the height in metres squared
2(kg/m ). Blood pressure was measured on the right 
arm using a mercury sphygmomanometer and 
appropriate cuff size with the subject seated for 5-
10 minutes. Diastolic blood pressure was recorded 
as the phase V Korotkoff sound. The blood pressure 
readings of the preceding two visits were extracted 
from patient records and an average of the three 
readings used for analysis.
Each subject had a spot mid-stream urine tested for 
proteinuria (Medi-Test Combi 2; sensitivity of 
10mg/dl). Fasting blood glucose (FBS) was 
estimated following an overnight fast by finger 
prick (capillary sample) using a standardised 
glucometer (LifeScan-Basic Plus-One Touch). 
Weekly calibration was performed according to the 
manufacturer's instructions. The last two FBS 
readings from the patient records were recorded, 
and the average of the three readings was used as an 
index of glycaemic control. Serum creatinine was 
estimated in the chemical pathology laboratory of 
the Jos University Teaching Hospital. 
We used the ADA strategies and goals for reno- and 
cardioprotection in patients with diabetic 
nephropathy to define categories of desirable and 
undesirable glycaemic control and blood pressure 
[9]. Good glycaemic control was defined as mean 
FBS in the range of 3.6 – 6.7mmol/L, and poor 
glycaemic control as mean FBS>6.7mmol/L. Good 
blood pressure control was defined as systolic BP≤
130mmHg and diastolic BP≤ 80mmHg in 
hypertensives or systolic BP<140mmHg and 
diastolic BP< 90mmHg in non-hypertensives. Poor 
blood pressure control was defined as values 
exceeding those limits.
An estimated sample size of 150 was calculated to 
allow a maximum 5% sampling error, and 160 
subjects were recruited to allow for missing data. A 
p-value of 0.05 was considered significant. Data 
were entered, checked and analysed in Epi Info 
3.2.2 (CDC, Atlanta, GA, USA). The chi-squared 
statistic and multiple logistic regression were used 
to test the association of patient characteristics with 
glycaemic control, blood pressure control, use of 
ACE inhibitors and proteinuria. Mean values of 
continuous variables were compared with the t-test.
Results
Patient characteristics
A total of 174 type 2 diabetic subjects were 
identified aged >30yrs at diagnosis and not insulin 
dependent. Five declined to participate, 7 were 
excluded due to incomplete past records, and two 
were too ill to participate, resulting in a total 
enrolment of 160. Their ages ranged from 32 to 85 
years with a mean (±SD) age of 54±10 years. About 
64% of subjects enrolled and studied were women 
as females tend to have better health seeking 
behaviour than men.   Most (70.6%) had diabetes 
for 5 years or less, and only 11.9% had the disease 
more than 10 years (Table 1). Most subjects (71.2%) 
were being treated for hypertension, of which 
almost half (45.6%) received monotherapy. The 
most common antihypertensive agents used were 
ACE inhibitors (64%), followed by calcium 
channel blockers (54%) and thiazide diuretics 
(33%). Up to 5.6% of subjects had blood pressures 
in the hypertensive range but were undiagnosed and 
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not on treatment. The mean fasting blood glucose 
was 7.6±2.6 mmol/L, and 54.4% had poor 
glycaemic control.
Nephropathy prevention strategies
Figure 1 displays the overlap between the three 
nephropathy prevention strategies considered in 
this study. Only five subjects (3.1%) had all three 
prevention strategies implemented successfully. A 
total of 23 (14.4%) did not have adequate control of 
any of the three factors considered.
1. Glycemic control
Table 2 shows the relationship of patient 
characteristics with control of glycaemia and blood 
pressure. Increasing duration of diabetes was 
significantly related to poor glycaemic control (p 
for linear trend= 0.01). Subjects on non-
pharmacologic therapy alone had significantly 
better glycaemic control than those on drug therapy 
(p= 0.02), although only 5% were not on drug 
therapy. Those on sulfonylurea monotherapy had 
significantly better glycaemic control and mean 
fasting blood glucose levels than those on other 
forms of therapy (p<0.01). Those using both 
insulin and oral hypoglycaemic agents had the 
worst glycaemic control and mean fasting blood 
glucose levels.
2. Control of hypertension
Hypertension was defined in subjects as a formal 
prior diagnosis of hypertension in their records on 
whatever treatment (lifestyle /drug). Those with no 
formal recorded diagnosis of hypertension were 
considered not to have hypertension, out of which 
those with SBP >140mmHg and or DBP 
>90mmHg were deemed to have undiagnosed 
hypertension.
A total of 51 (31.9%) had good blood pressure 
control (<140/90mmHg in non- hypertensives and 
<130/80mmHg in hypertensives). Increasing age 
was significantly related to an increasing mean 
systolic blood pressure (p= 0.04 for linear trend), 
but not to diastolic blood pressure (p=0.30) or 
overall blood pressure control (p=0.11).
3. ACE inhibitor use
Of all subjects, 46% were using ACE inhibitors, but 
only 14% had well-controlled blood pressure. Of 
hypertensives, 64% were getting ACE inhibitors 
but only 15% had well controlled blood pressure. 
ACE inhibitors were less likely to be used among 
those with good blood pressure control (OR 0.21, 
95% CI 0.11-0.45). In analysis limited to 
hypertensive subjects, ACE inhibitor use was not 
associated with good blood pressure control (OR 
1.28, 95% CI 0.37-6.3). Blood pressure control was 
not associated with gender, duration of diabetes, or 
BMI.
Proteinuria
Proteinuria was significantly more likely with 
increasing duration of diabetes (Table 3; p<0.01 for 
linear trend) and abnormal creatinine levels (OR 
3.2, 95% CI 1.0-10.4). Mean systolic blood pressure 
was 150±25 mm Hg and 134±18 mm Hg in those 
with and without proteinuria, respectively (p<0.01). 
A total of 17 subjects with uncontrolled 
hypertension and 8 with proteinuria were not 
receiving ACE inhibitors. Serum creatinine levels 
were significantly higher in those with proteinuria 
(12043 mcmol/L) than in those without proteinuria 
(9531 mcmol/L; p<0.01). Use of ACE inhibitors 
was not associated with less likelihood of 
proteinuria (p=0.17). Duration of diabetes (p<0.01), 
elevated creatinine (p<0.01), and elevated systolic 
blood pressure (p<0.01) were independently 
associated with proteinuria in a multiple logistic 
regression 
including all of these factors.
Discussion
This study provides evidence of poor control of risk 
factors for nephropathy in diabetic outpatients in 
north-central Nigeria. Studies focusing on 
management of diabetic nephropathy in 
nephropathy clinics have highlighted sub-optimal 
care, late referral, complexity of interventions, and 
the sheer size of the diabetic population as 
contributing to sub-optimal control of risk factors 
[11-16]. The gap between established treatment 
guidelines and their implementation is especially 
worrying in the light of the rapidly growing 
prevalence of diabetes [17]. Studies examining 
diabetes care in various clinical settings indicate 
that current practice is not achieving the goals for 
management of blood glucose, blood pressure, or 
serum lipids in individuals with diabetes [18]. The 
quality of care has been defined as “the degree to 
which health services for individuals and 
populations increase the likelihood of desired health 
outcomes are consistent with current professional 
knowledge”[19]. Even in high income countries 
only 11%, less than 80% and 56% of type 2 diabetics 
meet optimal levels for blood pressure control, 
haemoglobin A1c levels and angiotensin converting 
enzyme (ACE) inhibitor use, respectively [14, 20].
Despite the fact that all the diabetic subjects we 
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studied used some form of hypoglycaemic 
treatment, less than half of diabetic subjects in this 
study had good glycaemic control. In a U.S. general 
medicine clinic, 49% of patients on oral 
hypoglycaemic agents and 53% of African-
Americans with type 2 diabetes on insulin had well-
controlled glycaemia [16]. The third U.S. National 
Health and Nutritional Examination Survey 
(NHANES III) and the Behavioural Risk Factors 
Surveillance System (BRFSS) recorded good 
glycaemic control (HbA1c<9.5%) in 75% of 
subjects, but only 43% had HbA1c values below 
7% [14]. In the more recent NHANES IV, only 37% 
had HbA1c values below 7% [18]. However, direct 
comparison with these studies is limited, because 
we used average fasting blood glucose values 
rather than HbA1c as an index of glycaemic 
control. A mean fasting blood glucose <6.7mmol/L 
correlates well with a normal haemoglobin A1c 
level between 4-6% [21].
In this study, glycaemic control worsened with 
increasing duration of disease. This likely resulted 
from a decline in β-cell function with increasing 
duration of diabetes. Good glycaemic control was 
associated with sulfonylurea monotherapy and 
poor control with combined insulin and oral 
hypoglycaemic therapy, suggesting that the more 
severe the diabetes, the more difficult it is to 
control. Physicians may exercise excessive caution 
in prescribing multiple agents and insulin in order 
to avoid hypoglycaemia. Adherence is more 
difficult with multiple drugs, particularly in 
developing countries, because of increased cost, 
insulin storage requirements, infrequent use of self 
blood-glucose monitoring, and limited patient 
education personnel and resources.
Although 71% of diabetic patients were being 
treated for hypertension, only 9% had well 
controlled blood pressures (<130/80 mm Hg). In 
south-western Nigeria, only 11% of type 2 
diabetics on treatment for hypertension had blood 
pressures below 140/90 mm Hg [22]. Studies in 
Bahrain and Italy showed similar proportions of 
patients attaining target blood pressure levels of 
11% and 13%, respectively [23, 24]. In NHANES 
IV, 36% of diabetic subjects achieved target blood 
pressures below 130/80 mm Hg [18]. Blood 
pressure control may be more difficult to achieve in 
black Africans than in predominantly white 
popu l a t i ons .  The  cos t  o f  con t i nuous  
antihypertensive use is borne directly by patients in 
our setting, resulting in erratic adherence for a 
largely asymptomatic condition. We did not 
measure adherence to therapy, nor did we consider 
the many factors that influence adherence.
Encouragingly, we found that ACE inhibitors were 
the most frequently prescribed antihypertensive 
agents (64%). In another Nigeria centre, only 11.3% 
of hypertensive diabetics were prescribed ACE 
inhibitors [22]. An American analysis showed that 
use of RAAS blockade increased by 50% and 37% 
in two locations from 1997 to 2001 [25]. In another 
study 55% of diabetic patients were using RAAS 
blockade, of whom 39% had well controlled blood 
pressure [13]. Interestingly, more type 2 diabetics in 
our study received ACE inhibitors than had good 
glycaemic control or optimal blood pressure 
control. The low proportion with controlled blood 
pressure among our subjects using ACE inhibitors 
further buttresses the need for frequent review, 
dosage adjustment, and multiple antihypertensive 
agents to meet blood pressure targets. We did not 
evaluate the indications and contraindications to 
ACE inhibitors in individual subjects. This 
information would potentially have been useful in 
determining if the use of such drugs was below 
target levels. We did not test for microalbuminuria 
as an indication for RAAS blockade, as this 
investigation is not routinely available in Nigeria.
In terms of nephropathy prevention strategies, a 
total of 45% had adequate glycaemic control, 32% 
had optimal blood pressure control, and 46% were 
receiving ACE inhibitors. However only 3% of all 
subjects simultaneously had good glycaemic 
control, optimal blood pressure, and were receiving 
ACE inhibitors. These three cardinal targets, each 
independently capable of preventing the 
development of nephropathy, have a summative 
effect when used together. Multifactorial 
interventions are advocated for the prevention of 
chronic complications of diabetes, like nephropathy 
[10, 26]. 
Most of our subjects that had diabetes for 5 years or 
less, representing an ideal time for intervention to 
forestall future complications. However, in many 
resource-poor countries, guidelines are difficult to 
implement because of drug costs and limited 
resources. More studies are needed to assess the 
factors that contribute to non-adherence and failure 
to achieve set targets in developing country settings.
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Characteristic No. (%) 
Table 1: Characteristics of 160 Nigerians with Type 2 Diabetes 
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Table 2: Characteristics associated with Glycaemic and Blood Pressure Control  
Characteristic  Good glycaemic 
control
 
P value  Good blood pressure 
control
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Duration of Diabetes   <0.01* 
<1 yr 1 (3.7) 26 (96.3)  
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